Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.86 |
| ▸ | LCK | P06239 | 5/20 | 0.86 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.86 |
| ▸ | SRC | P12931 | 4/20 | 0.86 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.86 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.86 |
| ▸ | EPHB2 | P29323 | 3/20 | 0.86 |
| ▸ | KDR | P35968 | 3/20 | 0.86 |
| ▸ | ESYT2 | A0FGR8 | 2/20 | 0.86 |
| ▸ | NBAS | A2RRP1 | 2/20 | 0.86 |
| ▸ | CNOT1 | A5YKK6 | 2/20 | 0.86 |
| ▸ | TBKBP1 | A7MCY6 | 2/20 | 0.86 |
| ▸ | AGPS | O00116 | 2/20 | 0.86 |
| ▸ | MYO1F | O00160 | 2/20 | 0.86 |
| ▸ | SNAP23 | O00161 | 2/20 | 0.86 |
| ▸ | AP3B1 | O00203 | 2/20 | 0.86 |
| ▸ | PSMD12 | O00232 | 2/20 | 0.86 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.86 |
| ▸ | PGRMC1 | O00264 | 2/20 | 0.86 |
| ▸ | CLIC1 | O00299 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688472 | 1.00 | BRAF (0.86) | BRAFLCKMAPK14SRCDDR1 | |
| SCHEMBL29380618 | 0.92 | ABL1 (1.00) | BRAFLCKMAPK14SRCDDR1 | |
| SCHEMBL4699731 | 0.92 | ABL1 (1.00) | BRAFLCKMAPK14SRCDDR1 | |
| SCHEMBL29358745 | 0.92 | ABL1 (1.00) | BRAFLCKMAPK14SRCDDR1 | |
| SCHEMBL4697696 | 0.92 | BRAF (0.86) | BRAFLCKMAPK14SRCDDR1 | |
| SCHEMBL24532023 | 0.92 | BRAF (0.74) | BRAFLCKMAPK14SRCDDR1 | |
| SCHEMBL22024695 | 0.92 | BRAF (0.86) | BRAFLCKMAPK14SRCDDR1 | |
| SCHEMBL22024567 | 0.91 | BRAF (0.81) | BRAFLCKMAPK14SRCDDR1 | |
| SCHEMBL22025026 | 0.90 | BRAF (0.82) | BRAFLCKMAPK14SRCDDR1 | |
| SCHEMBL22025313 | 0.90 | BRAF (0.80) | BRAFLCKMAPK14SRCDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028133-A1 | RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220194943-A1 | RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2021050900-A1 | RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194943-A1 | RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER | EPHA1, EPHB2, EPHB1 | BRAF 52/4885LCK 29/4885MAPK14 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.